Laurence is an experienced regulatory professional and leader in the strategic and tactic aspects of new drug development and registration in China. He currently is Executive Director, Regulatory Affairs and Branded Generics Development, AstraZeneca China. He joined the pharmaceutical industry in 1995 as Regulatory Associate in Lilly China and took several manager positions in regulatory affairs, pharmacovigilance, IPR and industry affairs, as well as Regulatory Consultant in Lilly Asia on the regional new drug development till 2004 when he joined AZ as Regulatory Affairs Director.
Laurence received his BS degree in chemistry and MS degree in organic chemistry in Beijing Normal University. He also held a MBA diploma from CEIBS.
Since 1999 Laurence was an active participant and contributor to a lot of DIA activities including workshops, annual meetings in both China and USA/EU/Japan. He was the program committee member for the 4th, 5th DIA China annual meeting, the Program Chairperson for China Pharmacovigilance Workshop in 2012. He was also the speaker for several annual meetings in USA and Europe, and chaired the tutorial session on China regulatory introduction in USA annual meeting for three consecutive years. As one representative of DIA, he has been working closely with CPA for editing the internal journal “Global Pharmaceutical Forum” in the last two years. He is the member of DIA Advisory Committee China since 2010 and serves as Vice-Chairman since 2012.